Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Nasdaq Real Time Price USD

Jasper Therapeutics, Inc. (JSPRW)

Compare
0.1300
0.0000
(0.00%)
At close: April 2 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Ronald A. Martell President, CEO & Director 1.04M -- 1962
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Member of Scientific Advisory Board & Director 296.3k -- 1957
Mr. Herbert C. Cross CPA CFO & Corporate Secretary 659.84k -- 1972
Mr. Jeetinder Singh Mahal M.B.A. Chief Operating Officer 667.63k -- 1973
Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer 713.3k -- 1972
Mr. David Ku M.D. Vice President of Corporate Development, Portfolio Strategy & Management -- -- --
Mr. Matthew Ford Senior Vice President of Human Resources -- -- --
Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research & Translational Medicine -- -- --
Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations -- -- --
Ms. Patricia Carlos Senior Vice President of Regulatory Affairs & Quality -- -- --

Jasper Therapeutics, Inc.

2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400 https://jaspertx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
64

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Corporate Governance

Jasper Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.